Antipodes Partners’s ExxonMobil XOM Stock Holding History

Antipodes Partners’s Portfolio XOM Stock Details XOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,482,662	Closed	-$152M	–	41
2021 Q4	$152M	Sell	2,482,662 -424,148	-15%	-$26.5M	5.46%	6
2021 Q3	$171M	Buy	2,906,810 +338,639	+13%	+$19.3M	5.84%	5
2021 Q2	$162M	Buy	2,568,171 +365,176	+17%	+$21.8M	5.84%	2
2021 Q1	$123M	Buy	+2,202,995	New	+$116M	4.98%	6

Other funds holding XOM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Antipodes Partners's XOM Position: Q1 2022 in Review

Antipodes Partners sold out of ExxonMobil (XOM) in Q1 2022, closing a stake of 2,482,662 shares — an estimated $152M sold.

Antipodes Partners first reported a position in XOM in Q1 2021 and held it in 4 quarters. The position peaked at $171M in Q3 2021. 3,194 funds tracked by Wall St. Rank hold XOM as of Q1 2022.

Antipodes Partners reported no remaining ExxonMobil position as of Q1 2022 after selling out during the quarter.
Antipodes Partners sold 2,482,662 ExxonMobil shares in Q1 2022, an estimated $152M.
Antipodes Partners first reported a position in ExxonMobil in Q1 2021 and held it in 4 quarters.
Antipodes Partners's ExxonMobil position peaked at $171M in Q3 2021.
3,194 funds tracked by Wall St. Rank held ExxonMobil as of Q1 2022.

Based on Antipodes Partners's 13F filing for Q1 2022, filed 21 Apr 2022.